Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on February 26, 2019. The report details a revision to the terms of a previously announced rights offering and an update regarding the company's AMP-511 cost recovery program for chronic fatigue syndrome.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the structure of the rights offering:
- Unit Price: $1,000 per unit.
- Unit Composition: One share of Series B Convertible Preferred Stock (stated value $1,000) and 5,000 Warrants.
- Conversion Price: Reduced from $0.25 to $0.20 per share.
- Warrant Exercise Price: Reduced from $0.25 to $0.20 per share.
- Warrant Quantity: Increased from 4,000 to 5,000 per unit.
- Warrant Term: 5 years from issuance.
Material Changes Versus Prior Period
The company revised the terms of its rights offering to make the offering more attractive to investors. Key changes include:
- Decreased conversion price for Series B Convertible Preferred Stock to $0.20.
- Decreased warrant exercise price to $0.20.
- Increased the number of warrants per unit to 5,000.
- Added a trading volume condition to the company's right to redeem warrants.
- Modified the valuation provision for warrant repurchases in the event of a Fundamental Transaction.
Guidance, Outlook, and Management Commentary
Management Participation: All members of senior management and the Board of Directors plan to participate in the rights offering by exercising a portion of their respective rights.
Subscription Period: The offering remains open until 5:00 PM Eastern time on March 1, 2019, unless extended.
Regulatory Update: On February 22, 2019, the FDA reauthorized the company's annual extension for the AMP-511 cost recovery program. The FDA approved a cost recovery charge increase from $200 to $345 per vial. However, management stated they do not plan to apply this price increase in the near future.
Important Facts for Investor Verification
- Verify the final subscription amount raised in the rights offering after the March 1, 2019 deadline.
- Confirm the extent of participation by senior management and the Board of Directors.
- Monitor the company's decision on whether to implement the FDA-approved price increase for AMP-511.
- Review the specific trading volume conditions added to the warrant redemption rights.